Intranasal immunisation using recombinant Lactobacillus johnsonii as a new strategy to prevent allergic disease

Vaccine

Volumn 23, Issue 9, 2005, Pages 1126-1134

  Scheppler, Lorenz ^a   Vogel, Monique ^a   Marti, Pamela ^a   Müller, Lorenz ^a   Miescher, Sylvia M ^a,b   Stadler, Beda M ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b ZLB Behring   (Switzerland)

Author keywords

Anti idiotypic single chain fragment variable; IgE mimotope; Lactobacillus johnsonii

Indexed keywords

HYBRID PROTEIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PROTEINASE; RECOMBINANT LACTOBACILLUS JOHNSONII VACCINE; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VACCINE;

ALLERGIC DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL WALL; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG DELIVERY SYSTEM; DRUG POTENCY; IMMUNE RESPONSE; IMMUNIZATION; LACTOBACILLUS JOHNSONII; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VACCINATION;

AMINO ACID SEQUENCE; ANIMALS; BACTERIAL VACCINES; FEMALE; HYPERSENSITIVITY; IMMUNOGLOBULIN G; LACTOBACILLUS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS;

EID: 11144231085     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2004.08.031     Document Type: Article

References (38)

1. J. Corne, R. Djukanovic, L. Thomas, J. Warner, L. Botta, and B. Grandordy The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety, and pharmacokinetics J Clin Invest 99 1997 879 887
2. J.V. Fahy, H.E. Fleming, H.H. Wong, J.T. Liu, J.Q. Su, and J. Reimann The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects Am J Respir Crit Care Med 155 1997 1828 1834
3. K.S. Babu, and S.T. Holgate The role of anti-IgE therapies in the treatment of asthma Hosp Med 63 2002 483 486
4. A. Nayak, T. Casale, S.D. Miller, J. Condemi, M. McAlary, and A. Fowler-Taylor Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis Allergy Asthma Proc 24 2003 323 329
5. P. Chervinsky, T. Casale, R. Townley, I. Tripathy, S. Hedgecock, and A. Fowler-Taylor Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis Ann Allergy Asthma Immunol 91 2003 160 167
6. A. Finn, G. Gross, J. van Bavel, T. Lee, H. Windom, and F. Everhard Omalizumab improves asthma-related quality of life in patients with severe allergic asthma J Allergy Clin Immunol 111 2003 278 284
7. R.F. Lemanske Jr., A. Nayak, M. McAlary, F. Everhard, A. Fowler-Taylor, and N. Gupta Omalizumab improves asthma-related quality of life in children with allergic asthma Pediatrics 110 2002 e55
8. M. Soler Omalizumab, a monoclonal antibody against IgE for the treatment of allergic diseases Int J Clin Pract 55 2001 480 483
9. J.M. Knutti-Müller, B.M. Stadler, C.M. Magnusson, and C.M. de Weck Human IgE synthesis in vitro. Detection with monoclonal antibodies Allergy 41 1986 457 467
10. M.P. Rudolf, M. Vogel, F. Kricek, C. Ruf, A.W. Zurcher, and R. Reuschel Epitope-specific antibody response to IgE by mimotope immunization J Immunol 160 1998 3315 3321
11. J.K. Scott, and G.P. Smith Searching for peptide ligands with an epitope library Science 249 1990 386 390
12. C.F. Barbas 3rd, A.S. Kang, R.A. Lerner, and S.J. Benkovic Assembly of combinatorial antibody libraries on phage surfaces: the gene III site Proc Natl Acad Sci USA 88 1991 7978 7982
13. M. Vogel, S. Miescher, S. Kuhn, A.W. Zurcher, M.B. Stadler, and C. Ruf Mimicry of human IgE epitopes by anti-idiotypic antibodies J Mol Biol 298 2000 729 735
14. F. Kricek, C. Ruf, M.P. Rudolf, F. Effenberger, P. Mayer, and B.M. Stadler IgE-related peptide mimotopes. Basic structures for anti-allergy vaccine development Int Arch Allergy Immunol 118 1999 222 223
15. N.D. Zegers, E. Kluter, H. van Der Stap, E. van Dura, P. van Dalen, and M. Shaw Expression of the protective antigen of Bacillus anthracis by Lactobacillus casei: towards the development of an oral vaccine against anthrax J Appl Microbiol 87 1999 309 314
16. C. Grangette, H. Muller-Alouf, D. Goudercourt, M.C. Geoffroy, M. Turneer, and A. Mercenier Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum Infect Immun 69 2001 1547 1553
17. D.M. Shaw, B. Gaerthe, R.J. Leer, J.G. Van Der Stap, C. Smittenaar, and M. Heijne Den Bak-Glashouwer Engineering the microflora to vaccinate the mucosa: serum immunoglobulin G responses and activated draining cervical lymph nodes following mucosal application of tetanus toxin fragment C-expressing lactobacilli [In Process Citation] Immunology 100 2000 510 518
18. C.B. Maassen, J.D. Laman, M.J. den Bak-Glashouwer, F.J. Tielen, J.C. van Holten-Neelen, and L. Hoogteijling Instruments for oral disease-intervention strategies: recombinant Lactobacillus casei expressing tetanus toxin fragment C for vaccination or myelin proteins for oral tolerance induction in multiple sclerosis Vaccine 17 1999 2117 2128
19. C. Gilbert, D. Atlan, B. Blanc, R. Portailer, J.E. Germond, and L. Lapierre A new cell surface proteinase: sequencing and analysis of the prtB gene from Lactobacillus delbruekii subsp. bulgaricus J Bacteriol 178 1996 3059 3065
20. L. Scheppler, M. Vogel, A.W. Zuercher, M. Zuercher, J.E. Germond, and S.M. Miescher Recombinant Lactobacillus johnsonii as a mucosal vaccine delivery vehicle Vaccine 20 2002 2913 2920
21. C. Platteeuw, G. Simons, and W.M. de Vos Use of the Escherichia coli beta-glucuronidase (gusA) gene as a reporter gene for analyzing promoters in lactic acid bacteria [published erratum appears in Appl Environ Microbiol 1994 Jun;60(6):2207] Appl Environ Microbiol 60 1994 587 593
22. M.W. Pantoliano, R.E. Bird, S. Johnson, E.D. Asel, S.W. Dodd, and J.F. Wood Conformational stability, folding, and ligand-binding affinity of single-chain Fv immunoglobulin fragments expressed in Escherichia coli Biochemistry 30 1991 10117 10125
23. J.S. Huston, M. Mudgett-Hunter, M.S. Tai, J. McCartney, F. Warren, and E. Haber Protein engineering of single-chain Fv analogs and fusion proteins Methods Enzymol 203 1991 46 88
24. F. Hennecke, C. Krebber, and A. Pluckthun Non-repetitive single-chain Fv linkers selected by selectively infective phage (SIP) technology Protein Eng 11 1998 405 410
25. Y. Tang, N. Jiang, C. Parakh, and D. Hilvert Selection of linkers for a catalytic single-chain antibody using phage display technology J Biol Chem 271 1996 15682 15686
26. M.P. Rudolf, K. Furukawa, S. Miescher, M. Vogel, F. Kricek, and B.M. Stadler Effect of anti-IgE antibodies on Fc epsilonRI-bound IgE J Immunol 157 1996 5646 5652
27. U. Brinkmann, Y. Reiter, S.H. Jung, B. Lee, and I. Pastan A recombinant immunotoxin containing a disulfide-stabilized Fv fragment Proc Natl Acad Sci USA 90 1993 7538 7542
28. Y. Reiter, U. Brinkmann, S.H. Jung, B. Lee, P.G. Kasprzyk, and C.R. King Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment J Biol Chem 269 1994 18327 18331
29. Y. Reiter, U. Brinkmann, K.O. Webber, S.H. Jung, B. Lee, and I. Pastan Engineering interchain disulfide bonds into conserved framework regions of Fv fragments: improved biochemical characteristics of recombinant immunotoxins containing disulfide-stabilized Fv Protein Eng 7 1994 697 704
30. A. Worn, and A. Pluckthun Stability engineering of antibody single-chain Fv fragments J Mol Biol 305 2001 989 1010
31. C.R. Robinson, and R.T. Sauer Optimizing the stability of single-chain proteins by linker length and composition mutagenesis Proc Natl Acad Sci USA 95 1998 5929 5934
32. E. Gunneriusson, P. Samuelson, M. Uhlen, P.A. Nygren, and S. Stahl Surface display of a functional single-chain Fv antibody on staphylococci J Bacteriol 178 1996 1341 1346
33. C. Kruger, Y. Hu, Q. Pan, H. Marcotte, A. Hultberg, and D. Delwar In situ delivery of passive immunity by lactobacilli producing single-chain antibodies Nat Biotechnol 20 2002 702 706
34. A.W. Zuercher, S.M. Miescher, M. Vogel, M.P. Rudolf, M.B. Stadler, and B.M. Stadler Oral anti-IgE immunization with epitope-displaying phage Eur J Immunol 30 2000 128 135
35. L. Kirkeby, T.T. Rasmussen, J. Reinholdt, and M. Kilian Immunoglobulins in nasal secretions of healthy humans: structural integrity of secretory immunoglobulin A1 (IgA1) and occurrence of neutralizing antibodies to IgA1 proteases of nasal bacteria Clin Diagn Lab Immunol 7 2000 31 39
36. T.T. Rasmussen, L.P. Kirkeby, K. Poulsen, J. Reinholdt, and M. Kilian Resident aerobic microbiota of the adult human nasal cavity Apmis 108 2000 663 675
37. R. Poethke, M. Mader, I. Zedler, W. Beuche, K. Felgenhauer, and N. Kolbus A putative enzyme from various secretions specifically inhibits antibody-antigen interactions J Immunol Methods 191 1996 149 157
38. B.M. Stadler, A.W. Zurcher, S. Miescher, F. Kricek, and M. Vogel Mimotope and anti-idiotypic vaccines to induce an anti-IgE response Int Arch Allergy Immunol 118 1999 119 121